Opioid-free care for patients undergoing obesity surgery
Official title: Effects of an Opioid Sparing Care Pathway for Patients Undergoing Obesity Surgery
Run by Göteborg University · NCT03756961 · Data updated 2026-11-12
This study is testing if an opioid-free way to manage pain can help people recovering from obesity surgery feel better and heal faster compared to using traditional opioid medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Göteborg University Academic / other |
| Locations | 2 sites (Lindesberg, Region Örebro and 1 other locations) |
| Status | Recruiting |
| Started | May 1, 2019 |
| Main results expected | May 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | January 7, 2026 |
| Trial ID | NCT03756961 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older scheduled for laparoscopic obesity surgery.
✕Probably not a fit
Patients with serious comorbidities, psychiatric disorders, or those currently using opioids for chronic pain may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effects of an opioid-free care pathway compared to traditional opioid-based treatment for pain relief in patients undergoing obesity surgery. It aims to assess pain management, recovery quality, and opioid consumption through a randomized, non-blinded, multi-centre approach. The study will utilize various interventions, including dexmedetomidine and person-centred care, to explore their impact on postoperative outcomes. The research is approved by relevant authorities and spans from November 2018 to December 2022.
Why it matters
Potential benefit: If successful, this approach could lead to improved recovery and reduced reliance on opioids for pain management in obesity surgery patients.
How similar studies have gone: Other studies have shown promising results with opioid-sparing strategies, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: -Patients ≥18 years planned to undergo laparoscopic obesity surgery (GBP alt Sleeve surgery) at the selected site. Exclusion Criteria: * ASA\> III * Cardiovascular disease with bradycardia (\<50 bpm) * Serious liver disease failure * Insufficient knowledge of the Swedish language * Serious untreated psychiatric disease * Neurocognitive dysfunction * Pregnancy * Women of childbearing age without contraception * Malignant disease with expected short survival * Patients treated with opioids for chronic pain * Substance abuse * Hypersensitivity to Oxycodone, Esketamine, Dexmedetomidine, and Lidocaine * Pacemaker or ICD * Inability to fill in questionnaires * Decline participation,
Where it's running
-
Lindesberg Hospital
Lindesberg, Region Örebro, Sweden Recruiting -
Sahlgrenska University hospital/ Östra hopsital
Gothenburg, Vg, Sweden Recruiting
Study contacts
- Principal investigator: Sven-Egron Thörn, MD, PhD — Göteborg University
- Study coordinator: Axel Wolf, RN, PhD
- Email: axel.wolf@gu.se
- Phone: +46709355364
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.